Abstract: Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer.

Abstract: Disclosed herein is a WEE1 compound, or a pharmaceutically acceptable salt thereof, alone or in combination with a KRAS inhibitor, or a pharmaceutically acceptable salt thereof, for treating a disease or condition, such as a colorectal, pancreatic and/or non-small cell lung cancer.

Abstract: Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer.

Abstract: Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer.

Abstract: Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer.

Abstract: The present invention relates to the combination of Bcl-2 inhibitor Compound (A) in combination with a chemotherapeutic agent Compound (B) selected from azacitidine, bendamustine, bortezomib, carfilzomib, ixazomib, busulfan, carboplatin, cytarabine, cyclophosphamide, cladribine, cisplatin, capecitabine, decitabine, etoposide, fludarabine, gemcitabine, daunorubicin, doxorubicin, ifosfamide, methotrexate and vincristine, or a pharmaceutically acceptable salt of any of the foregoing, for the treatment of a disease or condition in particular hematological cancers.

Abstract: Disclosed herein are combination therapies of Bcl-2 inhibitors (Compound (A), along with pharmaceutically acceptable salts thereof) and CDK 4/6 inhibitors (Compound (B), along with pharmaceutically acceptable salts thereof) for treating a disease or condition, such as a cancer, including breast cancer and leukemia.

Abstract: Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a Bcl-2 inhibitor and a WEE1 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.

Abstract: Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a SERD inhibitor and a Bcl-2 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.

Abstract: Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a Bcl-2 inhibitor and a WEE1 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.

Abstract: Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a WEE1 inhibitor and a Bcl-2 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.